The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A
Blood Transfus. 2017 May;15(3):281-282.
doi: 10.2450/2017.0285-16.
Epub 2017 Mar 2.